Radiochemosensitivity and expression of p53 in patients with esophageal cancer treated by absolute noncurative resection

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 493-497

  Ikeguchi, Masahide ^a   Saito, Hiroaki ^a   Katano, Kuniyuki ^a   Kondou, Akira ^a   Tsujitani, Shunichi ^a   Maeta, Michio ^a   Kaibara, Nobuaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Esophageal cancer; p53; Prognosis; Radiochemotherapy

Indexed keywords

BLEOMYCIN; CISPLATIN; FLUOROURACIL; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; ESOPHAGUS CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MORTALITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

AGED; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031896818     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Nakayama K, Kinoshita Y: Surgical treatment combined with preoperative irradiation. JAMA 227: 178-181, 1974.
2. Marks RD, Scruggs HH, Wallace KM: Preoperative radiation therapy for carcinoma of the esophagus. Cancer 38: 84-89, 1976.
3. Maeta M, Koga S, Andachi H, Ishiguro M: Preoperative radiotherapy and intra-abdominal metastasis of the lymph node in the surgical treatment of carcinoma of the thoracic esophagus. Surgery, Gynecology & Obstetrics 165: 235-238, 1987.
4. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 57: 6304-6311, 1991.
5. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318-1327, 1993.
6. Zhan Q, Fan Sajan, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fornace Jr AJ. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9: 3743-3715, 1994.
7. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
8. Jung M, Notario V, Dritschilo A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res 52: 6390-6393, 1992.
9. Brachman DG, Beckett M, Graves D, Haraf D, Yokes E, Weichselbaum RR. p53 mutation does not correlate with radio sensitivity in 24 head and neck cancer cell lines. Cancer Res 53: 3667-3669, 1993.
10. Japanese Society for Esophageal Disease. Guidelines for the clinical and pathological studies on carcinoma of the esophagus. 8th ed. Tokyo: Kanehara, 1992.
11. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
12. Kawai K, Serizawa A, Hamana T, Tsutsumi Y: Heat-induced antigen retrieval of proliferating cell nuclear antigen and p53 protein in formalin-fixed, paraffin-embedded sections. Pathol Int 44: 759-764, 1994.
13. Finaly CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539, 1988.
14. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radio sensitivity of Burkitt's lymphoma cell lines. Cancer Res 53: 4776-4780, 1993.
15. Aas T, Børresen A-L, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 2: 811-814, 1996.
16. Bergh J, Norberg T. Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1: 1029-1034, 1995.
17. Kropveld A, Slootweg P, van Mansfeld ADM, Blankenstein MA, Hordijk GJ. Radioresistance and p53 status of T2 laryngeal carcinoma. Analysis by immunohistochemistry and denaturing gradient gel electrophoresis. Cancer 78: 991-997, 1996.
18. Kokoska MS, Piccirillo JF, Ei-Mofry SK, Emami B, Haughey BH, Scholnick SB. Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy. Cancer 78: 1693-1700, 1996.
19. Barten M, Ostwald C, Milde-Langosch K, Müller P, Wakusch Y, Löning T. HPV DNA and p53 alterations in oropharyngeal carcinomas. Virchows Arch 427: 153-157, 1995.